Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity

被引:65
|
作者
Singh, Nirbhai [1 ]
Tiem, Michelle [1 ]
Watkins, Ryan [1 ]
Cho, Yang Kyung [2 ]
Wang, Ying [1 ]
Olsen, Thomas [1 ]
Uehara, Hironori [1 ]
Mamalis, Christina [1 ]
Luo, Ling [3 ]
Oakey, Zackery [1 ]
Ambati, Balamurali K. [1 ]
机构
[1] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA
[2] Catholic Univ Korea, St Vincent Hosp, Suwon, Gyeonggi Provin, South Korea
[3] PLA, Hosp 306, Beijing, Peoples R China
基金
美国国家卫生研究院;
关键词
MURINE PENETRATING KERATOPLASTY; LYMPHATIC VESSELS; FACTOR-C; ENDOGENOUS INHIBITOR; VEGF RECEPTOR-3; TRANSGENIC MICE; GRAFT-SURVIVAL; LYMPHANGIOGENESIS; ANGIOGENESIS; EXPRESSION;
D O I
10.1182/blood-2012-08-453043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Corneal transparency is a prerequisite for optimal vision and in turn relies on an absence of blood and lymphatic vessels, which is remarkable given the cornea's proximity to vascularized tissues. Membrane-bound vascular endothelial growth factor receptor 3 (VEGFR-3), with its cognate ligand vascular endothelial growth factor C (VEGF-C), is a major mediator of lymphangiogenesis. Here, we demonstrate that the cornea expresses a novel truncated isoform of this molecule, soluble VEGFR-3 (sVEGFR-3), which is critical for corneal alymphaticity, by sequestering VEGF-C. sVEGFR-3 binds and sequesters VEGF-C, thereby blocking signaling through VEGFR-3 and suppressing lymphangiogenesis induced by VEGF-C. sVEGFR-3 knockdown leads to lymphangiogenesis and hemangiogenesis in the mouse cornea, while overexpression of sVEGFR-3 inhibits lymphangiogenesis and hemangiogenesis in a murine suture injury model. Pax6(+/-) mice spontaneously develop corneal and lymphatic vessels and are deficient in sVEGFR-3. sVEGFR-3 suppresses hemangiogenesis by blocking VEGF-C-induced phosphorylation of VEGFR-2. Overexpression of sVEGFR-3 leads to a 5-fold increase in corneal transplant survival in mouse models. sVEGFR-3 holds promise as a molecule to control and regress lymphatic-vessel-based dysfunction. Therefore, sVEGFR-3 has the potential to protect the injured cornea from opacification secondary to infection, inflammation, or transplant rejection.
引用
收藏
页码:4242 / 4249
页数:8
相关论文
共 50 条
  • [41] Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth, factor receptor-2 levels as a surrogate biomarker for tumor growth
    Ebos, John M. L.
    Lee, Christina R.
    Bogdanovic, Elena
    Alami, Jennifer
    Van Slyke, Paul
    Francia, Giulio
    Xu, Ping
    Mutsaers, Anthony J.
    Dumont, Daniel J.
    Kerbel, Robert S.
    CANCER RESEARCH, 2008, 68 (02) : 521 - 529
  • [42] Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer
    Hanseul Yang
    Chan Kim
    Min-Ju Kim
    Reto A Schwendener
    Kari Alitalo
    Warren Heston
    Injune Kim
    Wun-Jae Kim
    Gou Young Koh
    Molecular Cancer, 10
  • [43] Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer
    Yang, Hanseul
    Kim, Chan
    Kim, Min-Ju
    Schwendener, Reto A.
    Alitalo, Kari
    Heston, Warren
    Kim, Injune
    Kim, Wun-Jae
    Koh, Gou Young
    MOLECULAR CANCER, 2011, 10
  • [44] Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects
    Yu, De-Chao
    Lee, Jung-Sun
    Yoo, Ji Young
    Shin, Hyewon
    Deng, Hongxin
    Wei, Yuquan
    Yun, Chae-Ok
    MOLECULAR THERAPY, 2012, 20 (05) : 938 - 947
  • [45] Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth
    Laakkonen, Pirjo
    Waltari, Marika
    Holopainen, Tanja
    Takahashi, Takashi
    Pytowski, Bronislaw
    Steiner, Philipp
    Hicklin, Daniel
    Persaud, Kris
    Tonra, James R.
    Witte, Larry
    Alitalo, Kari
    CANCER RESEARCH, 2007, 67 (02) : 593 - 599
  • [46] Soluble vascular endothelial growth factor receptor1 contributes to the corneal antiangiogenic barrier (vol 91, pg 505, 2007)
    Ambati, B. K.
    Patterson, E.
    Jani, P.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (03) : 441 - 442
  • [47] Ovarian vascular endothelial growth factor and vascular endothelial growth factor receptor patterns in reproductive aging
    Yeh, John
    Kim, Beom Su
    Peresie, Jennifer
    FERTILITY AND STERILITY, 2008, 89 : 1546 - 1556
  • [48] Serum Placental Growth Factor, Vascular Endothelial Growth Factor, Soluble Vascular Endothelial Growth Factor Receptor-1 and -2 Levels in Periodontal Disease, and Adverse Pregnancy Outcomes
    Sert, Tuba
    Kirzioglu, F. Yesim
    Fentoglu, Ozlem
    Aylak, Firdevs
    Mungan, Tamer
    JOURNAL OF PERIODONTOLOGY, 2011, 82 (12) : 1735 - 1748
  • [49] VASCULAR ENDOTHELIAL GROWTH FACTOR A IN PATIENTS WITH ESSENTIAL HYPERTENSION
    Nebieridze, N.
    Natkina, D.
    Safronova, T.
    Podzolkov, V.
    JOURNAL OF HYPERTENSION, 2019, 37 : E211 - E211
  • [50] Galectin-3 Enhances Vascular Endothelial Growth Factor-A Receptor 2 Activity in the Presence of Vascular Endothelial Growth Factor
    Cano, Issahy
    Hu, Zhengping
    AbuSamra, Dina B. B.
    Saint-Geniez, Magali
    Ng, Yin Shan Eric
    Argueso, Pablo
    D'Amore, Patricia A. A.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9